Fierce FDA Debate Rages on Whether Drug OK Sets New Standard

  • FDA officials discussed Sarepta stock during deliberations
  • Drug approved on limited evidence after calls from patients

On Monday, the U.S. Food and Drug Administration went somewhere it has rarely gone before.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.